StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
12
Publishing Date
2023 - 05 - 01
1
2023 - 04 - 20
1
2023 - 02 - 28
1
2022 - 05 - 12
1
2022 - 03 - 25
1
2022 - 02 - 25
1
2022 - 02 - 17
1
2021 - 12 - 03
1
2021 - 09 - 21
1
2021 - 05 - 18
2
2021 - 02 - 03
1
Sector
Health technology
12
Tags
Acquisition
8
Agreement
9
Alliances
21
Antibody
14
Application
22
Approval
48
Biotech-bay
15
Cancer
107
Cell
22
Cell carcinoma
11
Chmp
17
Clinical-trials-phase-ii
15
Clinical-trials-phase-iii
20
Collaboration
34
Conference
18
Disease
22
Drug
63
Earnings
24
Europe
16
Events
24
Expected
9
Fda
20
Financial
21
Financial results
17
Food
24
Genetown
11
Global
67
Growing
13
Growth
35
Health
9
Immunotherapy
17
Int230
9
Iot
11
License
12
Lung
16
Market
125
N/a
325
Nivolumab
60
Opdivo
33
People
13
Pharm-country
67
Pharmaceutical
13
Pharmaceuticals
9
Phase 1
10
Phase 2
15
Phase 3
12
Positive
27
Product-news
14
Reach
12
Renal
11
Report
67
Research
80
Results
64
Solid tumors
10
Study
9
Therapeutics
48
Therapy
65
Treatment
93
Trial
48
Update
10
Entities
Abbott laboratories
1
Abeona therapeutics inc.
1
Agenus inc.
2
Biohaven pharmaceutical holding company ltd.
1
Bridgebio pharma, inc.
1
Bristol-myers squibb company
12
Sarepta therapeutics, inc.
1
Symbols
ABBV
5
ABEO
7
ADCT
6
ADEA
15
ADXS
6
AGEN
6
ALPMF
17
ALPMY
17
ALVO
8
AQST
5
AZN
16
BGNE
10
BIIB
16
BLIN
5
BMY
12
BNTX
6
CEVA
5
CHRS
6
CPRX
5
CRCW
5
DTIL
5
DYAI
6
EXEL
9
FBIO
9
GILD
13
GMAB
14
GNMSF
11
GSK
10
HALO
6
IDCC
8
IGT
5
IMGN
6
INCY
5
JAGX
6
JAZZ
5
JNJ
45
KMDA
9
LCTX
5
LLY
26
MDT
7
MESO
5
MRK
9
NVO
5
NVS
10
NVSEF
6
OTLK
5
PFE
19
PNT
5
QTRHF
6
SGEN
10
SNY
34
SNYNF
19
SRNE
14
TAK
13
TEVJF
11
TGTX
6
TMDI
6
TNXP
7
VYGR
6
XNCR
6
Exchanges
Nasdaq
4
Nyse
12
Crawled Date
2023 - 05 - 01
1
2023 - 04 - 20
1
2023 - 02 - 28
1
2022 - 05 - 12
1
2022 - 03 - 25
1
2022 - 02 - 25
1
2022 - 02 - 17
1
2021 - 12 - 03
1
2021 - 09 - 21
1
2021 - 05 - 18
2
2021 - 02 - 03
1
Crawled Time
11:00
1
12:00
3
12:15
1
12:30
1
13:00
4
16:00
1
20:00
1
Source
www.biospace.com
10
www.globenewswire.com
1
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
License
symbols :
Bmy
save search
U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
Published:
2023-05-01
(Crawled : 12:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-26.82%
|
O:
0.76%
H:
2.17%
C:
1.66%
reblozyl
fda
anemia
license
review
treatment
ema
application
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Published:
2023-04-20
(Crawled : 11:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-30.06%
|
O:
-0.23%
H:
0.16%
C:
-0.24%
license
cancer
treatment
agreement
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
Published:
2023-02-28
(Crawled : 16:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-30.19%
|
O:
-0.27%
H:
0.2%
C:
-1.2%
drug
application
opdivo
license
food
nivolumab
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
Published:
2022-05-12
(Crawled : 13:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-35.95%
|
O:
-0.28%
H:
0.34%
C:
0.29%
BBIO
|
$25.02
-1.73%
-1.76%
1.5M
|
Health Technology
|
315.78%
|
O:
-13.79%
H:
0.0%
C:
0.0%
bbp-398
license
potential
Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License Application
Published:
2022-03-25
(Crawled : 13:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-31.85%
|
O:
1.21%
H:
0.0%
C:
0.0%
reblozyl
application
drug
license
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
Published:
2022-02-25
(Crawled : 12:00)
- prnewswire.com
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-27.18%
|
O:
0.8%
H:
0.0%
C:
0.0%
BHVN
|
News
0 d
|
$38.72
-2.25%
-0.28%
970K
|
Health Technology
|
-71.06%
|
O:
-4.17%
H:
0.0%
C:
0.0%
license
phase 3
muscular atrophy
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi
Published:
2022-02-17
(Crawled : 13:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-27.72%
|
O:
-0.15%
H:
0.41%
C:
-0.16%
fda
application
drug
license
food
fda acceptance
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
Published:
2021-12-03
(Crawled : 12:30)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-11.29%
|
O:
1.53%
H:
0.0%
C:
0.0%
transfusion
application
drug
license
food
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
Published:
2021-09-21
(Crawled : 20:00)
- globenewswire.com
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-19.01%
|
O:
0.28%
H:
0.26%
C:
-0.58%
ABT
|
News
|
$106.89
-0.65%
-0.22%
5.1M
|
Health Technology
|
-14.58%
|
O:
0.3%
H:
0.19%
C:
-0.68%
SRPT
|
$124.27
6.11%
5.75%
1.3M
|
Health Technology
|
41.81%
|
O:
-0.25%
H:
1.24%
C:
0.08%
ABEO
|
News
|
$3.165
-7.19%
-7.74%
2.2M
|
Health Technology
|
161.98%
|
O:
-1.65%
H:
4.2%
C:
0.0%
license
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody ProgramAgenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Published:
2021-05-18
(Crawled : 12:15)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-25.36%
|
O:
-0.06%
H:
0.58%
C:
0.28%
AGEN
A
|
$7.42
14.86%
12.94%
1.3M
|
Health Technology
|
127.61%
|
O:
29.45%
H:
6.64%
C:
-6.87%
antibody
license
milestone
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
Published:
2021-05-18
(Crawled : 12:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-25.36%
|
O:
-0.06%
H:
0.58%
C:
0.28%
AGEN
A
|
$7.42
14.86%
12.94%
1.3M
|
Health Technology
|
127.61%
|
O:
29.45%
H:
6.64%
C:
-6.87%
antibody
license
Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
Published:
2021-02-03
(Crawled : 13:00)
- biospace.com/
BMY
|
$48.86
-0.27%
-0.02%
16M
|
Health Technology
|
-22.37%
|
O:
-0.11%
H:
0.54%
C:
-1.34%
covid
treatment
antibody
license
sars-cov-2
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.